

REMARKS

With entry of the present amendment, claims 1-47 are canceled and claims 48-76 are pending in the application.

Claims 48, 51, 61, 64, 75, and 76 recite a prepared epitope consisting of an amino acid sequence selected from the group set out in the claims. This amendment adds no new matter. Support for the amendment can be found throughout the specification, *e.g.*, in Table XXXVI at pages 203 and 204; page 111, page 157, page 160, page 163, and page 123.

Claims 49, 62, 50, 63, 69, 70, 71, and 72 recite a composition further comprising two (claims 49 and 62), three (claims 50, 63, 69), four (claim 70), five (claim 71), or six (claim 72) epitopes. This amendment adds no new matter. Support for the amendment can be found throughout the specification, *e.g.*, at page 30, lines 21-23; page 43, lines 3-4; page 45, lines 17-22; and page 48, lines 5-7.

Claims 52, 65, 53, and 66 recite a composition that further comprises an HTL epitope (claims 52 and 65) and an HTL epitope that is a pan DR binding molecule (claims 53 and 66). Support for the amendment can be found throughout the specification, *e.g.*, at page 43, line 31 through page 44, line 4 and page 52, lines 17-30.

Claims 57 and 58 recite an antigen presenting cell (claim 57) and an antigen-presenting cell that is a dendritic cell (claim 58). This amendment adds no new matter. Support for the amendment can be found throughout the specification, *e.g.*, at page 44, line 21 through page 45, line 4.

Claims 54 and 67 recite a peptide on or within a liposome. This amendment adds no new matter. Support for the amendment can be found throughout the specification, *e.g.*, at page 58, lines 4-25.

Claims 55 and 68 recite a peptide joined to a lipid. This amendment adds no new matter. Support for the amendment can be found throughout the specification, *e.g.*, at 43, lines 19-21.

Claim 61 recites a prepared peptide that is 250 amino acids or less in length. This amendment adds no new matter. Support for the amendment can be found throughout the specification, *e.g.*, at page 84, lines 14-17.


Claims 59 and 73, and 60 and 74, recite a composition further comprising a pharmaceutical excipient and an epitope in a unit dose form, respectively. This amendment adds no new matter. Support for the amendment can be found throughout the specification, *e.g.*, at page 58, lines 28-33 and page 57, lines 31-32, respectively.

Claim 62 recites at least two epitopes linked via a spacer. This amendment adds no new matter. Support for the amendment can be found throughout the specification, *e.g.*, at page 52, lines 22-30.

CONCLUSION

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Jean M. Lockyer
Reg. No. 44,879

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200
Fax: (415) 576-0300
JML
SF 1076787 v1